← Back to patent-cliff list
ATX-01 (Arthex Biotech)
Tier C — Watch / tradeATX-01 (Arthex Biotech)
Arthex Biotech SL
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Nucleic acid drug
Type
Targets：MicroRNAs
Indications (approved)：营养不良性肌强直, Osteoarthritis
Regional status
US
Phase II
2024-02-28
EU
-
2022-08-23
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of ATX-01 (Arthex Biotech)?
Approved indications include: 营养不良性肌强直, Osteoarthritis.
When does the ATX-01 (Arthex Biotech) patent expire?
No public expiry year is available for ATX-01 (Arthex Biotech) yet; this page updates once verified.
How do I get a quote for ATX-01 (Arthex Biotech) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01